Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

AstraZeneca cell therapy acquisition to advance in vivo therapies

1
SHARES

The company’s new acquisition, valued up to $1 billion, supports development of in vivo cancer treatments and the future of cell therapy.

AstraZeneca cell therapy in vivo cancer

Credit: Mats Wiklund / Shutterstock.com

AstraZeneca has agreed to acquire Belgian biotech EsoBiotec for up to $1 billion. The deal focuses on development of in vivo cell therapies, utilising EsoBiotec’s Engineered NanoBody Lentiviral (ENaBL) platform.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

EsoBiotec will receive an initial payment of $425 million once the deal has closed, plus up to $575 million based on development and regulatory milestones.

Their platform enables cell therapies to be administered via an IV injection and does not require immune cell depletion. By engineering immune cells in vivo (directly within the patient’s body), cell therapy treatments could be delivered in just minutes rather than weeks, which is the current process for these therapies, EsoBiotec explained. This helps to overcome key challenges in the field, such as cutting manufacturing timelines and improving patient access.

An opportunity to scale innovative cell therapies

“[AstraZeneca’s acquisition of EsoBiotec]… has the potential to transform cell therapy and will enable us to scale these innovative treatments so that many more patients around the world can access them”

“We are excited about the acquisition of EsoBiotec and the opportunity to rapidly advance their promising in vivo platform. We believe it has the potential to transform cell therapy and will enable us to scale these innovative treatments so that many more patients around the world can access them,” Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca commented.

The transaction is expected to close in Q2 of 2025, subject to customary closing conditions and regulatory clearances.

AstraZeneca’s recent investments

This news builds on AstraZeneca’s recent financial commitments, including in the US and Canada. The company announced a $3.5 billion investment in the US in November 2024, aligning with its aim to enhance its research and manufacturing footprint by the end of next 2026.

This multi-billion-dollar pledge, alongside AstraZeneca’s proposed $570 million US dollar investment in Canada in January, supports the firm’s goal to attain $80 billion in Total Revenue by the end of the decade.

Share via
Share via